Results of IVIS imaging indicated that compared to Nano-IFNγ/Zole in solution, preferable amount of zoledronate in the Nano-IFNγ/Zole in gel could retain in tumor lesions for more than 15 days, although a little amount of released zoledronate distributed to bones due to its bone-targeting property (Figure 3L, Figure S19). This evidence concerns the gene IFNG and neoplasm.